Modulating central nutrient-sensing and cell-growth signaling cascades remains a crucial strategy in targeting metabolic vulnerability across oncology. Detailed analysis within the Cancer Mtor Inhibitors Market report demonstrates how first-generation rapavelogs (everolimus, temsirolimus) and second-generation ATP-competitive mTORC1/mTORC2 kinase inhibitors disrupt cancer cell proliferation and...